CY1105648T1 - Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης - Google Patents
Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησηςInfo
- Publication number
- CY1105648T1 CY1105648T1 CY20061101438T CY061101438T CY1105648T1 CY 1105648 T1 CY1105648 T1 CY 1105648T1 CY 20061101438 T CY20061101438 T CY 20061101438T CY 061101438 T CY061101438 T CY 061101438T CY 1105648 T1 CY1105648 T1 CY 1105648T1
- Authority
- CY
- Cyprus
- Prior art keywords
- parkinson
- movement disorders
- disease
- extrapyramidal movement
- treatment
- Prior art date
Links
- 208000016285 Movement disease Diseases 0.000 title abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 3
- 229940035678 anti-parkinson drug Drugs 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 239000000939 antiparkinson agent Substances 0.000 abstract 2
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001647 drug administration Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Χρήση 2H-βενζιμιδαζολ-2-oνης, 1,3-διϋδρο-1-(2-{4-[τριφθορομεθυλ)φαινυλ]-1-πιπεραζινυλ}αιθυλ)- ή φυσιολογικώς αποδεκτού άλατος προσθήκης οξέος αυτής, για την βιομηχανική κατασκευή ενός φαρμάκου για την θεραπεία εξτραπυραμιδικών διαταραχών κίνησης. Αυτές οι εξτραπυριμιδικές διαταραχές κίνησης, μπορεί να προκύψουν από ιδιοπαθητική ασθένεια Parkinson, από τα αντίθετα αποτελέσματα της χορήγησης φαρμάκων κατά του Parkinson σε ιδιοπαθητική ασθένεια Parkinson, από δυσκινησίες που προκαλούνται από ιδιοπαθητική ασθένεια Parkinson, ή/ και μακροχρόνια χορήγηση φαρμάκου κατά του Parkinson, από σύνδρομα που ομοιάζουν με Parkinson ή σχετίζονται με Parkinson ή από Παρκινσονοειδή συμπτώματα. Άλλη άποψη της παρούσας εφεύρεσης αφορά φαρμακευτική σύνθεση περιλαμβάνουσα σαν δραστικά συστατικά -(I) 2Η-βενζιμιδαζολ-2-ονη, 1,3-διϋδρο-1-(2-{4-[3-τριφθορομεθυλ)φαινυλ]-1-πιπεραζινυλ}αιθυλ)- ή φυσιολογικώς αποδεκτό άλας προσθήκης οξέος αυτής και (II) τουλάχιστον ένα κατά του Parkinson φάρμακο σε συνδυασμό με ένα ή περισσότερα φαρμακευτικώς αποδεκτά έκδοχα.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111195A EP1256343B1 (en) | 2001-05-11 | 2001-05-11 | Flibanserin for the treatment of extrapyramidal movement disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105648T1 true CY1105648T1 (el) | 2010-12-22 |
Family
ID=8177363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101438T CY1105648T1 (el) | 2001-05-11 | 2006-10-05 | Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης |
Country Status (12)
Country | Link |
---|---|
US (1) | US8030314B2 (el) |
EP (1) | EP1256343B1 (el) |
JP (1) | JP4634008B2 (el) |
AT (1) | ATE332138T1 (el) |
AU (1) | AU2002310813B2 (el) |
CA (1) | CA2444062C (el) |
CY (1) | CY1105648T1 (el) |
DE (1) | DE60121301T2 (el) |
DK (1) | DK1256343T3 (el) |
ES (1) | ES2267627T3 (el) |
PT (1) | PT1256343E (el) |
WO (1) | WO2002092088A2 (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
DE10138273A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
ATE482699T1 (de) * | 2002-12-23 | 2010-10-15 | Merck Frosst Company | Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
NZ551340A (en) * | 2004-04-22 | 2010-10-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び/又は予防用の医薬組成物 |
WO2006096435A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
EP1904182A2 (en) * | 2005-05-06 | 2008-04-02 | Boehringer Ingelheim International GmbH | Method for the treatment of drug abuse with flibanserin |
CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
WO2006125042A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
JP2009513604A (ja) | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
EP1988898A2 (en) * | 2006-02-18 | 2008-11-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
JP5793828B2 (ja) | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
EP2056797A2 (en) | 2006-08-25 | 2009-05-13 | Boehringer Ingelheim International GmbH | Controlled release system and method for manufacturing the same |
CA2672957C (en) | 2006-12-20 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
DE102007009264A1 (de) * | 2007-02-26 | 2008-08-28 | Ellneuroxx Ltd. | 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen |
UY31335A1 (es) * | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69731658T2 (de) * | 1996-12-02 | 2005-12-01 | Merck Sharp & Dohme Ltd., Hoddesdon | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
FR2768338B1 (fr) * | 1997-09-17 | 1999-10-15 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la monoamine oxydase et leur application en therapeutique |
-
2001
- 2001-05-11 AT AT01111195T patent/ATE332138T1/de active
- 2001-05-11 EP EP01111195A patent/EP1256343B1/en not_active Expired - Lifetime
- 2001-05-11 DK DK01111195T patent/DK1256343T3/da active
- 2001-05-11 ES ES01111195T patent/ES2267627T3/es not_active Expired - Lifetime
- 2001-05-11 DE DE60121301T patent/DE60121301T2/de not_active Expired - Lifetime
- 2001-05-11 PT PT01111195T patent/PT1256343E/pt unknown
-
2002
- 2002-05-10 WO PCT/EP2002/005182 patent/WO2002092088A2/en active Application Filing
- 2002-05-10 US US10/473,525 patent/US8030314B2/en not_active Expired - Fee Related
- 2002-05-10 CA CA2444062A patent/CA2444062C/en not_active Expired - Fee Related
- 2002-05-10 AU AU2002310813A patent/AU2002310813B2/en not_active Ceased
- 2002-05-10 JP JP2002589005A patent/JP4634008B2/ja not_active Expired - Fee Related
-
2006
- 2006-10-05 CY CY20061101438T patent/CY1105648T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2004529175A (ja) | 2004-09-24 |
AU2002310813B2 (en) | 2008-04-03 |
DE60121301T2 (de) | 2007-07-19 |
CA2444062C (en) | 2011-02-22 |
WO2002092088A3 (en) | 2003-01-30 |
ES2267627T3 (es) | 2007-03-16 |
JP4634008B2 (ja) | 2011-02-16 |
DE60121301D1 (de) | 2006-08-17 |
PT1256343E (pt) | 2006-11-30 |
WO2002092088A2 (en) | 2002-11-21 |
EP1256343A1 (en) | 2002-11-13 |
ATE332138T1 (de) | 2006-07-15 |
US20040180904A1 (en) | 2004-09-16 |
DK1256343T3 (da) | 2006-10-30 |
US8030314B2 (en) | 2011-10-04 |
CA2444062A1 (en) | 2002-11-21 |
EP1256343B1 (en) | 2006-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105648T1 (el) | Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης | |
CY1118849T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
CY1117470T1 (el) | Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση | |
CY1105362T1 (el) | Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα | |
EA200301165A1 (ru) | Лекарственное средство на основе оксикодона | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
NO20051966L (no) | Nye pyrimidinamidderivater og anvendelse derav | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
BR0011867A (pt) | Preparação farmacêutica de levodopa/carbidopa/entacapona | |
HUP0402217A2 (hu) | Platinaszármazékot tartalmazó gyógyászati készítmények | |
CY1112562T1 (el) | Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης | |
CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
CY1106137T1 (el) | Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη | |
CY1111698T1 (el) | Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης | |
DE60313359D1 (de) | Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate | |
ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
ATE442158T1 (de) | Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form | |
HUP0402304A2 (hu) | Deutériummal helyettesített dihidrofuranonszármazékok és azokat tartalmazó gyógyszerkészítmények | |
ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
CY1105165T1 (el) | Φαρμακευτικη συνθεση που πepιλαμβανει συνδυασμο μετφορμινης και 4-οξοβουτανικου οξεος και η χρηση αυτης για τη θepαπεια του διαβητη | |
BR0114395A (pt) | Composição farmacêutica para administração por suprimento via oral | |
ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
CA2455621A1 (en) | Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders |